Please login to the form below

Not currently logged in
Email:
Password:

multiple myeloma

This page shows the latest multiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell is also preparing Fast CAR therapies for NHL and other haematological cancers such as multiple myeloma (MM).

Latest news

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    The deal adds to Celgene existing presence in cell therapy - it is working with  Bluebird Bio, on CAR-T therapy bb2121 for multiple myeloma, which is tipped to be a leader

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    On course to file before end of year. GlaxoSmithKline has more data backing its BCMA-targeting antibodydrug conjugate GSK2857916 in multiple myeloma, setting it on coursefor its first regulatory filings before ... was “excited about what this data

  • Imbruvica gains expanded use in Europe Imbruvica gains expanded use in Europe

    Despite this, AZ is looking to continue to make gains on Abbvie and Janssen, with reported studies testing the efficacy of Calquence in multiple myeloma, Waldenström's macroglobulinemia and diffuse large

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Surge in approvals and pipeline as merger nears. Celgene has reported higher-than-expected second-quarter revenues on the back of new triple therapy approvals for myeloma blockbusters Revlimid and Pomalyst. ... Revlimid gained on the back of its recent

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone for relapsed/refractory multiple myeloma, based on the ELOQUENT-3 trial. ... Finally, the panel recommended that Novartis’ multiple

More from news
Approximately 54 fully matching, plus 219 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Its most important pipeline candidate, however, is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Deal Watch October 2018

    treatment of multiple myeloma and other conditions. Joint development. agreement. $665m. ... Who’s the winner? We won’t know for many years. Multiple deals from Gilead too.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    ASCO last year, and a larger, 1, 000-patient study across multiple cancers is due to report in 2020. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in hard-to-treat

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Its fourth pipeline candidate is the multiple myeloma targeting CAR-T therapy bb2121, being co-developed with Celgene, which is tipped to be Bluebird’s potential blockbuster and therefore most crucial ... This is especially likely around its multiple

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics